Table 1.
Reported adverse cardiovascular events associated with cannabis, synthetic cannabinoids and cannabimimetics
| Acute coronary syndrome |
| Coronary thrombosis without atherosclerosisS1–S3 |
| Recurrent coronary thrombosisS4 |
| Acute myocardial infarction |
| Non-fatalS5–S8 |
| FatalS4 |
| Worsening of stable anginaS10–S12 |
| Coronary vasospasmS13–S18 |
| Recurrent coronary vasospasmS19 |
| Coronary no reflowS20,S21 |
| Cerebrovascular disease |
| Ischemic strokeS22–S28 |
| Recurrent stroke with re-challengeS29 |
| Stroke with posterior circulation predilectionS30, S31 |
| Cerebral vasospasmS32–S33 |
| Reversible cerebral vasoconstriction syndromeS34, S35 |
| Synthetic cannabinoid and acute cerebrovascular eventS36 |
| Congestive heart failure |
| Transient left ventricular regional ballooningS37, S38 |
| Acute congestive heart failureS39 |
| Synthetic cannabinoids and acute congestive heart failureS40, S41 |
| Diastolic dysfunctionS42 |
| Rhythm disturbances |
| Asystole and atrioventricular blockS43 |
| Increase in premature ventricular contractionsS44 |
| Ectopic atrial rhythmS45 |
| Atrial fibrillationS46, S47 |
| Ventricular tachycardiaS48 |
| Ventricular fibrillationS49 |
| Sudden cardiacdeathS50–S53 |
| Vasculopathy |
| Cannabis arteritisS54–S57 |
| Migratory thrombophlebitisS58 |
| Renal artery dissectionS59 |
| Central retinal vein occlusionS60 |
| Fetal cardiovascular complications |
| Maternal use and single ventricle physiologyS61 |
| Maternal use and transposition of great arteriesS62 |
| Paternal use and membranous ventricular septal defectsS63 |
| Intra-uterine growth retardationS64 |
| Miscellaneous |
| RhabdomyolysisS65 |
Superscript notations refer to references listed in Supplementary Appendix 1